These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 9374386

  • 1. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
    Punt CJ, Voest EE, Tueni E, Van Oosterom AT, Backx A, De Mulder PH, Hecquet B, Lucas C, Gerard B, Bleiberg H.
    Br J Cancer; 1997; 76(10):1376-81. PubMed ID: 9374386
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 3. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial.
    Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, Bastian G, Sarkany M, Schläpfer J, Giroux B, Leyvraz S.
    Ann Oncol; 1998 Nov; 9(11):1233-42. PubMed ID: 9862055
    [Abstract] [Full Text] [Related]

  • 4. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
    Julia AM, Roché H, Berlion M, Lucas C, Milano G, Robert J, Bizzari JP, Canal P.
    Br J Cancer; 1994 May; 69(5):868-74. PubMed ID: 8180016
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
    Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding MW, Von Hoff DD.
    J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB.
    J Clin Oncol; 2001 Jun 15; 19(12):2983-93. PubMed ID: 11408493
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
    Pérez V, Pierré A, Léonce S, Anstett M, Atassi G.
    Anticancer Res; 1993 Jun 15; 13(4):985-90. PubMed ID: 8352569
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
    Solary E, Mannone L, Moreau D, Caillot D, Casasnovas RO, Guy H, Grandjean M, Wolf JE, André F, Fenaux P, Canal P, Chauffert B, Wotawa A, Bayssas M, Genne P.
    Leukemia; 2000 Dec 15; 14(12):2085-94. PubMed ID: 11187897
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
    Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ.
    J Clin Oncol; 2001 Jun 15; 19(12):3130-41. PubMed ID: 11408511
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmén J, Anttila M, Ganesan TS, Harris AL, Talbot DC.
    Cancer Chemother Pharmacol; 2000 Jun 15; 46(1):27-34. PubMed ID: 10912574
    [Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies.
    Merlin JL, Guerci A, Marchal S, Missoum N, Ramacci C, Humbert JC, Tsuruo T, Guerci O.
    Blood; 1994 Jul 01; 84(1):262-9. PubMed ID: 7912556
    [Abstract] [Full Text] [Related]

  • 20. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B.
    Leukemia; 1996 Nov 01; 10(11):1741-50. PubMed ID: 8892677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.